Back to top
more

Theravance Biopharma, Inc. (TBPH)

(Delayed Data from NSDQ)

$17.31 USD

17.31
384,994

-0.18 (-1.03%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 23% (195 out of 253)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line

Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.

Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line

Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.

Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -18.37% and 3.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Verona (VRNA) Initiates Pivotal COPD Studies on Ensifentrine

Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.

Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma

With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe

Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.

Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2

Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.26% and -28.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

USANA (USNA) to Report Q2 Earnings: What's in the Cards?

USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.

Theravance Doses First Patient in Phase II Coronavirus Study

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling

Mylan (MYL) beats on Q1 earnings but misses on sales.

Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply

Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.

Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates

Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.

Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates

Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.